Company news

Rezolute, Inc. news in 2025

Rezolute, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

December 10, 2025

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 9, 2025

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

November 5, 2025

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

November 4, 2025

Rezolute to Participate in Upcoming Investor Conferences

October 14, 2025

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

September 16, 2025

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

September 1, 2025

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

August 19, 2025

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 21, 2025

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

July 8, 2025

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

May 27, 2025

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

May 4, 2025

Rezolute, Inc. Announces Closing of Underwritten Offering

April 24, 2025

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

April 22, 2025

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

April 22, 2025

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

March 25, 2025

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

February 11, 2025

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

February 3, 2025

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

January 30, 2025

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 6, 2025

Decks in 2025